The FAK inhibitor GSK2256098 is and has been tested in phase 1 and 2 studies for pulmonary hypertension and solid tumors, respectively (http://www.clinicaltrials.gov), whereas the FAK inhibitor PF573228 blocks CCN2 expression in vitro (Peidl et al. 2019). The gene discussed is PTK2; the disease is pulmonary hypertension.